前列腺癌的当代管理
Contemporary Management of Prostate Cancer.
作者信息
Cotter Katherine, Konety Badrinath, Ordonez Maria A
机构信息
Department of Urology, University of Minnesota, Minneapolis, Minnesota, 55455, USA.
出版信息
F1000Res. 2016 Feb 16;5. doi: 10.12688/f1000research.7183.1. eCollection 2016.
Abstract
Prostate cancer represents a spectrum ranging from low-grade, localized tumors to devastating metastatic disease. We discuss the general options for treatment and recent developments in the field.
摘要
前列腺癌涵盖了从低级别局限性肿瘤到极具破坏性的转移性疾病的一系列情况。我们将讨论该领域的一般治疗选择和最新进展。
相似文献
1
Contemporary Management of Prostate Cancer.前列腺癌的当代管理
F1000Res. 2016 Feb 16;5. doi: 10.12688/f1000research.7183.1. eCollection 2016.
2
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.E-钙黏蛋白在前列腺癌中的表达：一项使用高密度组织微阵列技术的广泛调查。
Hum Pathol. 2001 Jul;32(7):690-7. doi: 10.1053/hupa.2001.25902.
3
Imaging in prostate cancer.前列腺癌的影像学诊断。
Future Oncol. 2011 May;7(5):679-91. doi: 10.2217/fon.11.43.
4
20-year outcomes following conservative management of clinically localized prostate cancer.临床局限性前列腺癌保守治疗后的20年随访结果
JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095.
5
Results of conservative management of clinically localized prostate cancer.
N Engl J Med. 1994 Jan 27;330(4):242-8. doi: 10.1056/NEJM199401273300403.
6
Should we treat localized prostate cancer? An opinion.我们应该治疗局限性前列腺癌吗？一种观点。
Urology. 1995 Nov;46(5):607-16. doi: 10.1016/S0090-4295(99)80289-1.
7
Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.前列腺癌与放射治疗——血清前列腺特异性抗原所传达的信息
Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):23-35. doi: 10.1016/0360-3016(95)00154-Q.
8
Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.前列腺癌的临床表现、诊断及分期：来自美国国立癌症数据库的最新信息
Cancer. 2003 Sep 15;98(6):1169-78. doi: 10.1002/cncr.11635.
9
PSA and the conservative treatment of early prostate cancer.前列腺特异性抗原（PSA）与早期前列腺癌的保守治疗
Arch Ital Urol Androl. 2006 Dec;78(4):152-3.
10
Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA.
J Med Liban. 2005 Apr-Jun;53(2):95-102.
引用本文的文献
1
A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts.用于患者来源异种移植物体外培养的 3D 可灌注平台。
Adv Healthc Mater. 2023 Jun;12(14):e2201434. doi: 10.1002/adhm.202201434. Epub 2023 Jan 8.
2
Mechanisms of decision-making in preoperative assessment for older adult prostate cancer patients-A qualitative study.老年前列腺癌患者术前评估决策机制的定性研究。
J Surg Oncol. 2020 Mar;121(3):561-569. doi: 10.1002/jso.25819. Epub 2019 Dec 23.
3
DNA Damage Response in Prostate Cancer.前列腺癌中的 DNA 损伤反应。
Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):a030486. doi: 10.1101/cshperspect.a030486.
4
Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES.我们是否低估了前列腺癌治疗后的尿失禁发生率？来自美国国家健康与营养检查调查（NHANES）的结果。
Int Urol Nephrol. 2017 Oct;49(10):1715-1721. doi: 10.1007/s11255-017-1660-5. Epub 2017 Jul 14.
本文引用的文献
1
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
2
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.用于前列腺癌的新型及下一代雄激素受体导向疗法：超越阿比特龙和恩杂鲁胺。
Urol Oncol. 2016 Aug;34(8):348-55. doi: 10.1016/j.urolonc.2015.05.025. Epub 2015 Jul 7.
3
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.18F-氟甲基胆碱与 68Ga-PSMA PET/CT 在经治愈性治疗后 PSA 升高且正在考虑靶向治疗的前列腺癌患者中的前瞻性比较。
J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.
4
A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.106 例初诊时远处转移性前列腺癌行根治性前列腺切除术的围手术期结局的多机构分析。
Eur Urol. 2016 May;69(5):788-94. doi: 10.1016/j.eururo.2015.05.023. Epub 2015 May 30.
5
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.MR/超声融合引导活检与超声引导活检诊断前列腺癌的比较。
JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.
6
The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy.磁共振成像引导下前列腺穿刺活检在对前列腺癌根治术患者进行包膜外侵犯风险分层中的作用
J Urol. 2015 Jul;194(1):105-111. doi: 10.1016/j.juro.2015.01.072. Epub 2015 Jan 23.
7
Serum markers in prostate cancer detection.前列腺癌检测中的血清标志物。
Curr Opin Urol. 2015 Jan;25(1):59-64. doi: 10.1097/MOU.0000000000000128.
8
A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).一项针对局限性前列腺癌男性患者聚焦不可逆电穿孔的前瞻性发展研究：纳米刀电穿孔消融试验（NEAT）。
Contemp Clin Trials. 2014 Sep;39(1):57-65. doi: 10.1016/j.cct.2014.07.006. Epub 2014 Jul 26.
9
Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.前列腺特异性抗原和前列腺特异性抗原速率作为¹¹C-醋酸盐PET/CTAC扫描检测前列腺癌复发的阈值指标。
Clin Nucl Med. 2014 Sep;39(9):777-83. doi: 10.1097/RLU.0000000000000516.
10
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.癌症治疗的未来：选择可能对PD1/L1阻断疗法有反应的患者。
Clin Cancer Res. 2014 Oct 1;20(19):4982-4. doi: 10.1158/1078-0432.CCR-14-0933. Epub 2014 Jun 26.
Zotero 插件